El-Sissy Azza H, El-Mashari May A, Bassuni Wafaa Y, El-Swaayed Aziza F
Department of Pathology, King Fahad Medical City, Riyadh, KSA, Egypt.
J Egypt Natl Canc Inst. 2006 Sep;18(3):244-9.
Immunophenotyping improves both accuracy and reproducibility of acute leukemia classification and is considered particularly useful for identifying aberrant lineage association of acute leukemia, biphenotypic and bilineal acute leukemia, as well as monitoring minimal residual disease. Some immunophenotypes correlate with cytogenetic abnormalities and prognosis.
Is to determine aberrant lymphoid antigen expression in Saudi acute myeloid leukemia (AML), correlate them with FAB subtypes, evaluate early surface markers CD7 and CD56, and to investigate the role of cytoplasmic CD79a (a B cell marker that is assigned a high score of 2.0 in the WHO classification).
Thirty four newly diagnosed AML cases were included in this study, 47% showed aberrant lymphoid antigen expression. CD9 was the most frequently expressed lymphoid antigen (29.4%) followed by CD7 & CD19 (11.8%), CD4 (8.8%) and CD22 (2.9%). CD9 was expressed in 3/6 (50%) of M3 cases, CD7 was expressed in 11.8% and was mostly confined to FAB M1 and M2 and associated with immature antigens CD34, HLA-DR and TdT. CD56 was expressed in 7/34 (20.6%) cases, three of these cases (42.9%) belonged to the monocytic group. CD56 was also detected in 2 cases with 11q23 rearrangement. CD56 was expressed in 2/7 (28.6%) M2 cases, and was associated with t (8;21) (q22;q22) together with CD19. Co-expression of CD56 and CD7 was detected in 2.9% of the cases. CD79a was expressed in one case together with CD19, diagnosed as acute biphenotypic leukemia, and was associated with t(8;21) (q22;q22).
Minimal residual disease in AML is very difficult to trace, detection of aberrant expression of lymphoid antigens will make it easier. The high score given to CD79a by EGIL is questionable based on cytogenetic classification.
免疫表型分析提高了急性白血病分类的准确性和可重复性，被认为对识别急性白血病的异常谱系关联、双表型和双系急性白血病以及监测微小残留病特别有用。一些免疫表型与细胞遗传学异常及预后相关。
是确定沙特急性髓系白血病（AML）中异常淋巴样抗原的表达，将它们与FAB亚型相关联，评估早期表面标志物CD7和CD56，并研究细胞质CD79a（一种B细胞标志物，在世界卫生组织分类中被赋予2.0的高分）的作用。
本研究纳入了34例新诊断的AML病例，47%表现出异常淋巴样抗原表达。CD9是最常表达的淋巴样抗原（29.4%），其次是CD7和CD19（11.8%）、CD4（8.8%）和CD22（2.9%）。CD9在3/6（50%）的M3病例中表达，CD7在11.8%的病例中表达，且大多局限于FAB M1和M2型，并与未成熟抗原CD34、HLA-DR和TdT相关。CD56在7/34（20.6%）的病例中表达，其中3例（42.9%）属于单核细胞组。CD56在2例11q23重排的病例中也被检测到。CD56在2/7（28.6%）的M2病例中表达，并与t（8；21）（q22；q22）以及CD19相关。2.9%的病例中检测到CD56和CD7的共表达。CD79a在1例病例中与CD19共同表达，诊断为急性双表型白血病，并与t（8；21）（q22；q22）相关。
AML中的微小残留病很难追踪，检测淋巴样抗原的异常表达将使其更容易。基于细胞遗传学分类，EGIL给予CD79a的高分值得怀疑。
